RPC-1063
Drug
Celgene Corporation
Total Payments
$7.4M
Transactions
637
Doctors
18
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $7.4M | 637 | 18 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.4M | 637 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202) | Celgene Corporation | $1.7M | 3 |
| PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) | Celgene Corporation | $1.3M | 8 |
| PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) | Celgene Corporation | $1.2M | 1 |
| (RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) (RPC01-3101) | Celgene Corporation | $1.1M | 1 |
| Ph III Yellowstone CD OLE (RPC01-3204) (BMS Study Number: IM047-P17) (RPC01-3204) | Celgene Corporation | $840,756 | 1 |
| Ph III Yellowstone CD Maintenance (RPC01-3203) (BMS Study Number: IM047-P16) (RPC01-3203) | Celgene Corporation | $761,578 | 0 |
| PhIII Efficacy And Safety of RPC1063 in Relapsing MS (RPC01-3001) (RPC01-3001) | Celgene Corporation | $318,646 | 0 |
| PhII Stepstone RPC1063 Induction in Moderately to Severely CD as Induction with LT(RPC01-2201) (BMS Study Number: IM047-P13) (RPC01-2201) | Celgene Corporation | $127,350 | 3 |
| A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients (RPC01-201) | Celgene Corporation | $15,272 | 4 |
| A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects with Eosinophilic Esophagitis (RPC02-201) | Celgene Corporation | $14,330 | 5 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients (RPC01-301) | Celgene Corporation | $12,416 | 4 |
| A Phase 1 study to characterize the pharmacokinetics and pharmacodynamics of ozanimod following administration of different multiple-dose regimens in healthy adult caucasian and japanese subjects (RPC01-1911) | Celgene Corporation | $1,144 | 1 |
Top Doctors Receiving Payments for RPC-1063
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $7.3M | 606 |
| , MD | Gastroenterology | Hollywood, FL | $34,441 | 2 |
| , M.D | Gastroenterology | West Haven, CT | $19,513 | 3 |
| , M.D | Neurology | San Francisco, CA | $9,924 | 4 |
| , MD | Neurology | Cleveland, OH | $8,304 | 3 |
| , M.D | Gastroenterology | Los Angeles, CA | $7,175 | 2 |
| Amit Bar-Or | Neurology | Philadelphia, PA | $6,684 | 2 |
| , MD | Neurology | Stanford, CA | $6,208 | 2 |
| , M.D | Cardiovascular Disease | Charlottesville, VA | $4,675 | 1 |
| , MD | Pediatric Gastroenterology | Peoria, IL | $2,866 | 1 |
| Ikuo Hirano | — | Chicago, IL | $2,866 | 1 |
| , M.D., M.P.H | Gastroenterology | Chapel Hill, NC | $2,866 | 1 |
| , M.D | Allergy & Immunology | Cincinnati, OH | $2,866 | 1 |
| , M.D | Pediatric Pathology | Cincinnati, OH | $2,866 | 1 |
| , MD | Gastroenterology | Atlanta, GA | $2,030 | 2 |
| , M.D | Gastroenterology | San Diego, CA | $2,030 | 2 |
| , MD | Clinical Pathology/Laboratory Medicine | Scottsdale, AZ | $1,144 | 1 |
| , MD | Neurology | Westerville, OH | $1,144 | 1 |
| , MD | Gastroenterology | Chicago, IL | $1,144 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $7.4M
Product Information
- Type Drug
- Total Payments $7.4M
- Total Doctors 18
- Transactions 637
About RPC-1063
RPC-1063 is a drug associated with $7.4M in payments to 18 healthcare providers, recorded across 637 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $7.4M was paid across 637 transactions to 18 doctors.
The most common payment nature for RPC-1063 is "Unspecified" ($7.4M, 100.0% of total).
RPC-1063 is associated with 12 research studies, including "PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202)" ($1.7M).